enVVeno Medical Corp
Business
enVVeno Medical Corporation is a medical device company developing innovative bioprosthetic venous valve solutions for the treatment of chronic venous insufficiency and venous ulcers. The company's lead product, the enVVe System, is a first-in-class, non-surgical, transcatheter-delivered replacement venous valve designed to restore one-way blood flow in the deep venous system of the leg. The company manufactures its products in an ISO 13485-certified facility in Irvine, California, and is pursuing FDA pre-market approval through the PMA pathway, with pivotal clinical trials expected to begin in 2026.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development expenses | 10 | 12 | 14 | 10 | 6 | |
| Selling, general and administrative expenses | 11 | 12 | 12 | 15 | 11 | |
| Loss from operations | −21 | −24 | −25 | −25 | −17 | |
| Realized gain from sales of trading securities | 1 | 2 | 1 | 53,000 | — | |
| Unrealized loss from trading securities | −400,000 | −22,000 | 468,000 | 49,000 | — | |
| Interest income | 692,000 | 389,000 | 180,000 | 161,000 | — | |
| Total other income | 1 | 2 | 2 | 263,000 | −365,000 | |
| Net loss | −19 | −22 | −24 | −25 | −17 | |
| Net loss per basic common share | −33.06 | −44.53 | −1.91 | −2.2 | −1.9 | |
| Net loss per diluted common share | −33.06 | −44.53 | −1.91 | −2.2 | — | |
| Basic | 589,000 | 490,000 | 12 | 11 | 9 | |
| Diluted | 589,000 | 490,000 | 12 | 11 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 2 | 4 | 5 | 55 | |
| Short-term investments | 25 | 41 | 43 | 34 | — | |
| Prepaid expenses and other current assets | 614,000 | 581,000 | 511,000 | 392,000 | 312,000 | |
| Total current assets | 29 | 44 | 47 | 39 | 55 | |
| Property and equipment, net | 51,000 | 182,000 | 334,000 | 521,000 | 618,000 | |
| Operating lease right-of-use assets, net | 654,000 | 1 | 1 | 2 | 2 | |
| Security deposits and other assets | 31,000 | 31,000 | 31,000 | 31,000 | 54,000 | |
| Total assets | 30 | 45 | 49 | 42 | 58 | |
| Accounts payable, accrued expenses and other current liabilities | 2 | 2 | — | 568,000 | 729,000 | |
| Current portion of operating lease liabilities | 390,000 | 364,000 | 338,000 | 314,000 | 291,000 | |
| Total current liabilities | 2 | 2 | 1 | 2 | 2 | |
| Long-term operating lease liabilities | 310,000 | 700,000 | 1 | 1 | 2 | |
| Total liabilities | 2 | 3 | 2 | 3 | 3 | |
| Commitments and Contingencies Note 10 | — | — | — | — | — | |
| Preferred stock, par value $0.00001, 10,000 shares authorized: no shares issued or outstanding | — | — | — | — | — | |
| Common stock, par value $0.00001, 250,000 shares authorized, 656 and 501 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — | — | — | — | |
| Additional paid-in capital | 198 | 194 | 176 | 145 | 136 | |
| Accumulated deficit | −171 | −152 | −130 | −107 | −82 | |
| Total stockholders equity | 27 | 42 | 46 | 39 | 54 | |
| Total liabilities and stockholders equity | 30 | 45 | 49 | 42 | 58 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3 | 4 | 5 | 9 | 6 | |
| Depreciation and amortization | 136,000 | 189,000 | 220,000 | 212,000 | 149,000 | |
| Amortization of right-of-use assets | 353,000 | 339,000 | 326,000 | 313,000 | 304,000 | |
| Prepaid expenses and other current assets | −33,000 | −70,000 | −119,000 | −80,000 | −38,000 | |
| Accounts payable, accrued expenses and other current liabilities | 1,000 | 698,000 | −183,000 | — | — | |
| Operating lease liabilities | −364,000 | −338,000 | −314,000 | −290,000 | −313,000 | |
| Net cash used in operating activities | −16 | −17 | −19 | −16 | −12 | |
| Maturities of investments | 62 | 57 | 49 | 14 | — | |
| Purchase of investments | −46 | −56 | −57 | −48 | — | |
| Purchases of property and equipment | −5,000 | −37,000 | −33,000 | −115,000 | −368,000 | |
| Net cash provided by investing activities | 16 | 1 | −8 | −35 | −368,000 | |
| Proceeds from the sale of common stock and pre-funded warrants in public offering, net of fees | — | 14 | — | — | — | |
| Proceeds from sale of common stock in At-the-Market offering, net of fees | 782,000 | — | — | — | — | |
| Proceeds from exercise of warrants | 241,000 | — | — | — | 245,000 | |
| Proceeds from exercise of stock options | — | 46,000 | — | — | — | |
| Net cash provided by financing activities | 1 | 14 | 26 | — | 58 | |
| Net increase (decrease) in cash and cash equivalents | 1 | −2 | −935,000 | −50 | 45 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is enVVeno Medical Corp's CIK number?
enVVeno Medical Corp's SEC CIK number is 0001661053 (1661053). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find enVVeno Medical Corp's SEC filings?
All of enVVeno Medical Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did enVVeno Medical Corp last report earnings?
enVVeno Medical Corp (NVNO) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-019485). This is enVVeno Medical Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is enVVeno Medical Corp's most recent earnings 8-K?
enVVeno Medical Corp's latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0001493152-26-019485. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View enVVeno Medical Corp's latest earnings 8-K →
Look up any company's CIK number →